The difference between teriflunomide and ofatumumab

Ofatumumab (Ofatumumab) is a fully human anti-CD20 monoclonal antibody that can be self-administered by patients for the treatment of relapsing multiple sclerosis (MS). In the same Phase III trial in pan>ms adult patients, subcutaneous ofatumumab was more effective than oral teriflunomide in reducing annual relapse rates, reducing MRI-detected lesion activity, and limiting worsening disability.

Ofatumumab is a monoclonal antibody that induces B cell apoptosis and immune cell-mediated killing by binding toCD20 antigen. It is mainly used to treat a variety of B-cell malignancies, such as chronic lymphocytic leukemia. It is also approved for multiple sclerosis and is generally administered by subcutaneous injection. Teriflunomide is an immunomodulator that reduces the number of activated central nervous system lymphocytes, thereby producing anti-inflammatory and anti-proliferative effects, and is used to treat patients with relapsing-remitting multiple sclerosis. Teriflunomide blocks pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, which may be related to its immunomodulatory effect in MS. Teriflunomide is taken orally in pill form.

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.